Introduction
Benzene is a ubiquitous environmental contaminant that produces bone marrow toxicity and various types of cancer in both humans and animals (IARC, 1982; Huff et al., 1989) . While the mechanism(s) by which benzene exerts its carcinogenicity is unclear, animal studies involving partial hepatectomies (Sammett et al., 1979) and induction or inhibition of liver enzymes (Andrews et al., 1977; Kenyon et al., 1996) suggest that hepatic metabolism plays a critical role in toxicity. The primary route of benzene metabolism, shown in Figure 1 , presumably involves oxidation by liver enzymes to produce the reactive intermediate, benzene oxide (BO) (Snyder et al., 1993; Medinsky et al., 1989; Kalf, 1987) , which is in equilibrium with its oxepin (Vogel and Günther, 1967) . BO can rearrange nonenzymatically to form phenol (Jerina and Daly, 1974) , react with water to generate benzene-1,2-dihydrodiol, or proceed through a series of reactions which result in the ring open product, muconaldehyde (Witz et al., 1996; Witz et al., 1990; Bleasdale et al., 1996) . BO also binds covalently with glutathione to produce a premercapturic acid (Snyder and Hedli, 1996) and with various other nucleophiles to produce adducts of proteins and (presumably) DNA in blood, bone marrow, and other tissues (Norpoth et al., 1988; Norpoth et al., 1996; Melikian et al., 1992; Bechtold et al., 1992a; McDonald et al., 1994; Yeowell-O'Connell et al., 1996a; Bechtold et al., 1992b; Yeowell-O'Connell et al., 1996b) . Benzene-1,2-dihydrodiol and phenol subsequently give rise to catechol (1,2-dihydroxybenzene) and hydroquinone, which can be oxidized to 1,2-and 1,4-benzoquinone, respectively (Snyder and Hedli, 1996) . Indeed, most recent research on benzeneinduced carcinogenesis has focused on these quinones and upon trans, transmuconaldehyde compounds that are toxic to bone marrow and have been shown to form DNA adducts Smith et al., 1989; Pfeiffer and Irons, 1983; Rushmore et al., 1983; Jowa et al., 1990; Levay et al., 1991; Schatz-Kornbrust et al., 1991) . However, recent evidence that large background levels of the benzoquinones exist in the blood of humans and rodents (McDonald et al., 1994; McDonald et al., 1993) and the lack of evidence that trans, trans-muconaldehyde escapes the livers of benzene-dosed animals (Witz et al., 1996) raises doubts that these particular metabolites are solely responsible for the toxic effects of benzene.
Surprisingly little attention has been paid to the possible role that BO might play in the carcinogenicity of benzene, despite the facts that BO is the primary benzene metabolite, is electrophilic and forms adducts with cellular macromolecules, and is probably genotoxic. Indeed, N 7 -phenylguanine (a likely DNA adduct of BO) has been observed in the urine of benzene-dosed rats (Norpoth et al., 1988; Norpoth et al., 1996) and, in the only cancer bioassay reported to date, BO produced lung tumors in newborn mice (Busby et al., 1990) . The paucity of investigations regarding the disposition of BO in vivo may reflect a widely held belief that this molecule is too reactive to diffuse out of the hepatocyte after its formation (Medinsky et al., 1989) or may simply point to measurement problems. Certainly, BO has never been detected following the metabolism of benzene either in vivo or in vitro. However, measurements of S-phenylcysteine, a purported protein adduct of BO, in the Hb, albumin, and bone marrow proteins of rats and mice (Bechtold et al., 1992a; McDonald et al., 1994; Bechtold et al., 1992b) and in the Hb and serum albumin of benzene-exposed workers (Bechtold et al., 1992b; Yeowell-O'Connell et al., 1996b) , provide indirect evidence that BO was present in the blood and other tissues following benzene metabolism.
Given the potential importance of BO in the carcinogenesis of benzene, we investigated the stability of BO in rat blood in vitro and the production of BO in the blood of rats following a single oral administration of benzene (400 mg/kg body weight). Remarkably, our results show that BO is relatively stable in rat blood and that a significant fraction of the metabolized dose of benzene is released as BO into the systemic circulation.
Materials and Methods
BO was synthesized by dehydrohalogenation of 4,5-dibromo-1,2-epoxycyclohexane (generously provided by B. Golding, University of Newcastle, U.K.) using DBU in anhydrous diethylether at a 1:4 molar ratio, in a manner similar to that described by Gillard et al. (1991) . The structure and purity of the final product were confirmed by GC-MS and proton NMR.
Eighteen to 20-week-old, male, F344 rats (250-330 g) were used in these experiments. To determine the half-life of BO in blood in vitro, a 0.37 mg/ml solution of BO in acetone was added to 0.37-ml aliquots of blood (obtained from three animals) to provide a final concentration of 37 µM and incubated at 37 °C. Immediately after incubation, samples were analyzed via GC-MS, using toluene as the internal standard. For the in vivo experiment, 19 rats were administered a single dosage of 400 mg benzene/kg body weight in 1 ml of corn oil via gastric intubation. Two animals each were sacrificed at 0.25, 0.75, 1.5, 3, 6, 9, 12, 14 , and 24 h following administration (only one animal at 14 h), and two control animals were sacrificed 1.5 h following administration of corn oil only. The blood samples were extracted and analyzed by GC-MS. The blood dose of BO was estimated by trapezoidal integration of the area under the blood-concentration-time curve (AUC), using a nonlinear graphing program (GraphPad Prism from GraphPad Software, San Diego, CA).
Results
The elimination of BO from rat blood in vitro is illustrated in Figure 2 as a plot of the natural logarithm of the BO/toluene peak-area ratio versus time. A clear linear relationship was observed (r 2 = 0.993), indicating that BO was eliminated under pseudo-first order kinetics from rat blood at an initial concentration of 37 mM. The slope of this relationship was estimated to be -5.24 h -1 (S.E. = 0.10), corresponding to a half-life of 7.9 min.
Benzene and BO were not detected in the blood of control animals. Among the animals to which benzene had been administered, the levels of benzene in blood reached peak values (37-62 µg/ml) within 15 min of administration. As shown in Figure 3A , these blood concentrations of benzene were maintained for 3-6 h and then declined to nondetectable levels by 24 h postadministration. The kinetic behavior of BO in blood exhibited a similar pattern to that of benzene, as shown in Figure 3B . During the first 0.75 h post-administration, the BO concentrations reached peak levels of 8-11 ng/ml (about 0.09 µM), which were sustained for 8-9 h, and then declined exponentially to 1.5-2.6 ng/ml at 12-14 h and to nondetectable values at 24 h. The estimate of the AUC for BO was 103 ng-h/ml.
Discussion
These results have several obvious implications. Most importantly, the unambiguous presence of BO in the blood of benzene-dosed animals confirms the prevailing hypothesis that BO represents the first step of benzene metabolism. Furthermore, with a half-life of about 8 min in rat blood, BO can easily be distributed throughout the body after being formed in the liver. This half-life is considerably longer and, therefore, difficult to reconcile with one reported for BO in 1 M KCl at 30°C, which was less than 2 min (Jerina and Daly, 1974) . Indeed, our estimated half-life of 7.9 min suggests that BO is relatively stable in a medium which contains large concentrations of reactive nucleophiles, including glutathione.
Since BO is clearly present in the general circulation following benzene metabolism, it should be able to form adducts with a wide range of nucleophilic macromolecules, including DNA and proteins, as suggested previously with measurements of N 7 -phenylguanine in the urine (Norpoth et al., 1988; Norpoth et al., 1996) and S-phenylcysteine in the blood and bone marrow of benzene-dosed rodents (Bechtold et al., 1992a; McDonald et al., 1994; Bechtold et al., 1992b) . While these results do not preclude the possibility that BO is also formed in situ in these tissues, they are sufficient to account for the observed adduct formation and support the use of S-phenylcysteine as a biomarker of benzene exposure in humans (Bechtold et al., 1992b; Yeowell-O'Connell et al., 1996b) .
We estimated the AUC for BO in blood to be 103 ng-h/ml from time zero to 24 h. Assuming a blood volume of 16.0 ml for a 0.295-kg rat (Donaldson, 1924) , this AUC is equivalent to 150 nmol-h/ kg body weight. Using a published PBPK model (Medinsky et al., 1989) , we predict that the total metabolism of benzene in a F344 rat, at a dosage of 400 mg/kg body weight, would be 1380 nmol-h/kg body weight. Thus, we infer that approximately 4.3% of the metabolized dose of benzene was released as BO from the liver (or other metabolizing tissue) into the systemic circulation.
Because BO is the primary metabolite formed during benzene metabolism, we expect that the blood dose of BO should be much larger than that of the other electrophilic benzene metabolites produced at later stages, including the benzoquinones and trans, transmuconaldehyde. For example, McDonald et al. (1993) used cysteinyl adducts of Hb to estimate a blood dose of 125 pM-h 1,4-benzoquinone-h/mg benzene/kg body weight. In contrast, we estimate a blood dose of 2.74 x 10 3 pM BO-h/mg benzene/kg body weight, which is about 22 times greater than that of 1,4-benzoquinone. Given the abundance of BO in the blood relative to the other electrophilic metabolites, we suggest that BO may well contribute to the genotoxicity of benzene. Carcinogenesis, 14, 1921 Carcinogenesis, 14, -1925 Carcinogenesis, 14, , 1993 McDonald, T. M., K. Yeowell-O'Connell, and S. M.
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